VTUS

VENTRUS BIOSCIENCES INC Financials

moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboardSee who Ventrus is hiring next, click here to view […]

Ventrus Biosciences Receives Date for Type B Pre-NDA Meeting With FDA for DOLIZEM (Diltiazem Hydrochloride Cream) in Anal Fissures

[GlobeNewswire] – NEW YORK — Ventrus Biosciences, Inc. , a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that, in response to a request from the company, the … moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboardSee who Ventrus is hiring next, click here to view […]

Ventrus Biosciences Announces Results From Second Pivotal Phase 3 Trial of Diltiazem Cream (VEN 307) in Patients With Anal Fissure

[GlobeNewswire] – NEW YORK — Ventrus Biosciences, Inc. today announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related … moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboardSee who Ventrus is hiring next, click here […]

Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference

[at noodls] – NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) — Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that Dr. … moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboardSee who Ventrus is hiring next, click here to view […]

Ventrus Biosciences Announces Full Exercise of Overallotment Option by Underwriters

[at noodls] – NEW YORK, Feb. 7, 2013 (GLOBE NEWSWIRE) — Ventrus Biosciences, Inc. (Nasdaq:VTUS) today announced that the underwriter of its previously announced public offering of common stock has exercised in full … moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboardSee who Ventrus is hiring next, click here to view […]

Ventrus Biosciences Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock

[at noodls] – NEW YORK, Jan. 29, 2013 (GLOBE NEWSWIRE) — Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that it is concurrently offering to sell, subject to market and other conditions, (i) shares of its common … moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboardSee who Ventrus is hiring next, click here […]

Ventrus Biosciences Reports Third Quarter 2012 Financial Results

[at noodls] – NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) — Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the third quarter ended September 30, 2012….This is an abstract of the original … moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: FDA Confirms Necessity of Ventrus’ Second Phase III

[ACN Newswire] – By Jake KingAs expected, the FDA will require Ventrus Biosciences (NASDAQ:VTUS) to complete a second Phase III study of diltiazem hydrochloride cream (VEN-307) before submitting a New Drug Application … moreView todays social media effects on VTUSView the latest stocks trending across Twitter. Click to view dashboard […]